India’s drug regulator has mandated pharmaceutical companies to establish robust systems for tracking and reporting adverse drug reactions. This directive, stemming from Schedule M of the Drugs and Cosmetics Rules, reinforces the critical need for post-marketing surveillance to ensure patient safety. The move aligns with a global push for real-world safety data to identify rare or delayed side effects.
